Why Is Everyone Talking About Bristol Myers Squibb Stock?

Last year, large-cap pharmaceutical company Bristol Myers Squibb (NYSE: BMY) completed its $74 billion acquisition of cancer biotech company Celgene, creating one of the largest biopharma companies in the world in terms of market cap. However, investors are now worried that the acquisition has caused Bristol Myers Squibb to enter into financial constraints due to COVID-19.

As a result, shares are down more than 12% year to date, compared to the S&P 500 index's 4% decline. In my opinion, I think investors' fears are overblown. In this article, I will tackle why Bristol Myers Squibb is a solid buy due to its growth, dividend, and value prospects.

Source Fool.com